Drugs / ANOC-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07145450 | Jul 2025 → Apr 2030 expected | pancreatic ductal adenocarcinoma | Anocca AB | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-03-17 | Anocca AB | Regulatory Anocca Announces Authorisation of Clinical Trial Application to Start First In-Human Trial in Advanced Pancreatic Cancer anocca.com ↗
Anocca AB, a leading T-cell immunotherapy company, announces the authorisation of its Clinical Trial Application (CTA) from the regulatory authorities in four European countries under the European Union’s (EU) harmonised framework, for VIDAR-1, with Germany acting as the reference state. |
| 2024-11-26 | Anocca AB | Regulatory Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer anocca.com ↗
Application to the European Medicines Agency (EMA) covers ANOC-001 as the initial product in the company’s VIDAR-1 Phase I/II multi-asset programme targeting mutated KRAS in advanced pancreatic cancer. |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANOC-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07145450 ↗ |
| Modality | Cell therapy | “engineered autologous T cells” NCT07145450 ↗ |
| Route | Intravenous | “administered by a single IV infusion” NCT07145450 ↗ |
| Target | KRAS | “TCR targeting KRAS G12V” NCT07145450 ↗ |